One of the biggest risks to any AI tool is data integrity. Cybersecurity is built on the CIA triad of confidentiality, integrity and availability. What I often advise is to protect the data model for ...

FICO stakes a claim that narrow will be broad with the launch of its Focused Foundation Model for Financial Services and its financial Focused Language Models (FLMs).

For pharmaceutical scientists, the integration of artificial intelligence (AI) and machine learning (ML) into workflows represents a fundamental paradigm shift in how the industry discovers, develops, ...

Perforce Software, the DevOps company for global teams seeking AI innovation at scale, announced the findings of the 2025 State of Data Compliance and Security Report. This comprehensive research ...

Digital transformation is a pressing concern among leading pharma firms. Credit: Gorodenkoff / Shutterstock. Few industries have innovated more prodigiously than biopharma over recent years. But its ...

Databricks is acquiring Mooncake to accelerate its no ETL vision, where AI agents can build applications on unified data without the costly plumbing that connects transactional and analytical systems ...

GlobalData's AI tool 'Likelihood of Approval (LoA)' model, powered by artificial intelligence (AI), accurately predicts pharmaceutical drug approvals with an 85% success rate. Learn how this tool ...

While a number of Confluent customers have begun moving artificial intelligence (AI) proofs-of-concept (PoCs) into production in the past six months, they often encounter stumbling blocks when the ...

F, outlines an approach that involves real-time data ingestion, foundation model fine-tuning and agentic workflows.

Pharma R&D faces rising trial complexity, high costs, and patient and investigator shortages, driving the need for adaptive models and data-driven strategies to speed therapies to market.

Artificial intelligence has taken many forms over the years and is still evolving. Will machines soon surpass human knowledge and understanding?

Billionaire-led hedge funds with exceptional track records purchased stock in Nvidia and Palantir during the second quarter.